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Abstract 
Introduction 
There is a growing number of clinical trials in patients with head and neck cancer. Although 
not often the primary outcome, patient reported outcomes (PROs) are now an important 
component. The aim of this structured review was to identify and report the characteristics of 
the questionnaires used and summarise the findings in the literature. 
 
Materials and methods 
A search of several online databases was devised using the following key terms: head and 
neck oncology, head and neck surgery, reconstruction, clinical trials patient-reported 
outcomes, questionnaires, Quality of Life (QoL), validated instruments, and patient 
satisfaction. Information was collected relating to the topic of the paper, sample size, 
selection criteria, the main advantages and disadvantages of the PRO used, and if the tool was 
used in conjunction with any other. 
 
Results 
1342 papers were screened, of which 54 articles eligible; across these papers, 22 
questionnaires were identified. The primary reason for utilising a tool was its relevance to the 
focus of the paper; including features such as xerostomia, pain, swallowing to name a few. 
 
Discussion  
We recommend that outcome measures for clinical trials should be chosen in relation to the 
following criteria: appropriateness, reliability, validity, responsiveness, precision, 
interpretability, acceptability and feasibility; to allow the patient experience to be the focus of 
the primary outcome. Clinical trials use validated questionnaires but the PRO measures 
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tended not to be the focus of the trial. There is merit in future clinical trials having PRO 
measures as the primary outcome and designed around an explicit hypothesis. 
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Introduction 
Measurement of patient QoL is imperative as UK head and neck cancer incidence is 
increasing.1 The associated debilitating physiological and psychological morbidities may thus 
become more prevalent2. Side effects of treatment and functional difficulties can exacerbate 
emotional distress, depression, and self-esteem issues. The scope of randomised controlled 
trials in head and neck cancer is treatment; many compare toxicity of different treatment 
regimens or provide ideal interventions for side effects such as xerostomia. However, there is 
no universal instrument that is sufficiently robust to compare QoL and morbidity in patients 
followed up after initial surgical resection, chemotherapy and radiotherapy3. 
 
Clinicians find it difficult to determine precisely what physical and emotional trauma affects 
each patient after initial head and neck cancer management, and to what severity. However, it 
is these very effects that affect adherence, compliance, morbidity and mortality4. It is here 
that patient-related outcomes become paramount. This review aims to summarise the 
literature in respect to the PROM used, the focus of the research and the key clinical findings. 
 
Materials and methods 
A search strategy was devised using the following key terms: head and neck oncology, head 
and neck surgery, reconstruction, clinical trials, patient-reported outcomes, questionnaires, 
QoL, validated instruments, and patient satisfaction. The following databases were examined: 
Handle-on-qol, Medline, Ebase (Excerpta Medica), HAPI (Health and Psychosocial 
Instruments), Science Citation Index/Social Sciences Citation Index, Ovid Evidence-Based 
Medicine databases and PsychINFO. 
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Only manuscripts written in English were included. All instruments included in the review 
were identified as PROMs measuring head and neck-related QoL and/or satisfaction that had 
undergone development and validation with head and neck cancer patients. For the appraisal 
of the psychometric and operational performance of the instruments we looked for evidence 
of criteria as in Table 1. PRISMA guidance was considered in the search and presentation of 
the results5. A total of 2072 papers were identified describing QoL (QOL) measures. From an 
evaluation of the abstracts and available full text, 54 relevant papers were closely examined 
(Figure 1). 
 
Results 
From 54 papers6-59, the authors found 22 QoL measures, which satisfied our inclusion criteria 
(Figure 1). In many studies the authors used more than one instrument. The most common 
tool used in the search was the EORTC QLQ C30, with its use in 18 of the 54 papers. The 
second most common was the EORTC QLQ-H&N35 tool which was used in 14 papers. The 
above two instruments are intended to be utilised together, which was the case in 11 papers. 
 
The primary reason for utilisation of a tool was for its ability to be general or specific when 
measuring QoL (Table 2). Papers favoured tools that were well-validated, easy to use, and 
those that had a focus on functional and psychological aspects of QoL. Conversely, 
disadvantages were deemed to be a lack of relevance to the focus of the paper, low levels of 
completion, and those that required large numbers for statistical significance. Table 3 
summarises the main foci of the clinical trials. 
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Discussion 
In the included papers, PROMs are generally utilised as a secondary outcome to quantify the 
effect of a treatment modality, rather than as a primary outcome in relation to the patient 
experience. In undertaking this review, the authors are aware of its limitations: by including 
papers only written in English, there is exclusion of a potentially large number of studies that 
could give further insight into how PROMs are utilised. In addition, there were restrictions in 
obtaining further papers by an inability to access the full text in our searches. The authors 
recommend that outcome measures for clinical trials should be chosen in relation to the 
criteria stated in Table 1. Analysis of the papers allows us to determine the key focus of the 
trial and why each PRO instrument was utilised. 
 
General Instruments 
EQ-5D assesses mobility, self-care, usual activities, pain and anxiety. The instrument was 
developed for clinical and economic evaluation of healthcare and was designed for use 
alongside condition-specific instruments59. The instrument was used by one study19, assessing 
PET-CT surveillance versus neck dissection in advanced head and neck cancer. EQ-5D was 
used along with EORTC QLQ-C30, H&N35 and MD Anderson Dysphagia Index (Table 4). 
Mehanna et al19 commented on the utilisation of EQ-5D in deriving quality adjusted life years 
to assess economic viability between the treatment groups. 
 
COOP-WONCA Functional status charts assess general functional status aimed at primary 
care; the domains include: physical fitness, feelings, daily activities, social activities, change 
in health and overall health. COOP-WONCA charts were used by Van Bokhorst et al22 in 
their trial assessing perioperative enteral nutrition and QoL of severely malnourished patients. 
The COOP-WONCA charts are not specific for cancer and so were used along with EORTC 
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QLQ-C30. Van Bokhorst concluded that the COOP-WONCA charts were not sensitive 
enough to pick up significant changes in QoL22. 
 
Cancer-specific Instruments 
EORTC QLQ C30 consists of a general QoL questionnaire composed of functional scales, 
symptom scales, a global health status and QoL status. The questionnaire was acceptable to 
patients with 60% completing it in less than 30 minutes61. Eighteen randomised control trials 
used the EORTC QLQ C30, more than any other measure (Table 4). Eleven studies used 
EORTC QLQ C30 with the QLQ-H&N35 as is intended. The focus of most papers which 
utilised EORTC QLQ C30 was different chemotherapy medications and their effectiveness. 
 
The Spitzer QoL index covers 5 domains: activity, daily living, health, support and outlook. 
The instrument was used by two studies in the review, Robert et al49 were assessing a novel 
chemotherapy regime and Elliot et al50 were measuring the effectiveness of a medication in 
preventing radiation mucositis. It was commented that if one question in the index is not 
answered the results cannot be interpreted which could be an issue in smaller studies; in 
addition, the index may be subject to patient and reviewer bias50. 
 
The Rotterdam Symptom checklist consists of four main scales: physical symptom distress, 
psychological distress, activity level, and overall valuation of life. Griffiths et al51 were the 
only trial to use this instrument. The paper assessed QoL in patients on the continuous hyper-
fractionated accelerated radiotherapy randomised trial, which showed there was no clear 
difference in QoL compared to conventional radiotherapy. The authors modified the checklist 
by adding four domains: cough, coughing up blood, hoarseness and restlessness. Griffiths51 
used the RSCL alongside the Hospital Anxiety and Depression Scale. 
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Head and Neck Cancer-specific Instruments 
The EORTC Head and Neck cancer module (QLQ-H&N35) is a module which is designed to 
be used in conjunction with the EORTC QLQ C30. This consists of scales including pain, 
swallowing, senses, speech, social eating, social contact and sexuality. 11 papers used the 
EORTC QLQ C30 in conjunction with QLQ-H&N35, 7 used EORTC QLQ C30 without the 
Head and neck module and 3 used the QLQ-H&N35 without the EORTC QLQ C30 (Table 
4). The focus the papers was in the comparison of different treatment regimes, particularly 
chemotherapeutic agents which was the case for 7 of the 11 papers. 
 
The QoL Radiation Therapy Instrument (QoL-RTI) is designed specifically for radiation 
therapy. The instrument was used by one study in our search which was assessing the effect 
of a novel radiotherapy regime. The regime showed QoL returned to baseline after 1 month 
of treatment and it had acceptable toxicity. The instrument was acceptable to patients with 
90% completing both pre-treatment and end of treatment questionnaires, but compliance 
reduced between month 3 and month 12 post treatment58. 
 
The University of Washington QoL questionnaire is a head and neck-specific instrument. 9 
papers used the UoWQoL (Table 4), two of which used it in conjunction with the Neck 
Dissection Impairment Index and the University of Michigan Xerostomia Questionnaire. The 
purpose of most the papers was to assess the effectiveness of different radioprotective 
regimes during radiotherapy; however, most papers saw that there was still a decrease in QoL 
despite intervention. The authors of these papers praised the UoWQoL as a general health 
measure but commented that it was insensitive to changes regarding xerostomia. Owen et al34 
found a lack of compliance to completion. 
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The ROTG modified University of Washington Head and Neck Symptom Questionnaire is 
essentially the same as the UoWQoL but focuses more on the effects of radiation in the head 
and neck38. It is used by three studies assessing the symptoms of patients undergoing 
radiotherapy who found that there is a negative change in QoL scores following treatment, 
particularly in relation to mucositis and xerostomia38,39,40 (Table 4). 
 
The University of Michigan Xerostomia-related QoL scale is specific to mouth and throat 
dryness. Four of the papers included used this instrument, all of which measured QoL in 
different radiotherapy techniques; those with parotid-sparing had an increase in QoL 
compared to other regimes (Table 4). 
 
The Neck Dissection impairment index (NDII) is designed to assess function, particularly 
related to the shoulder, following neck dissection. This instrument was used in two studies to 
assess the effects of different treatments, including exercises and TENS, on QoL. There was 
found to be no statistical significance between treatments in either study. Both studies used 
the index along with more general head and neck indices for an overall view of QoL. The 
NDII was praised for its simplicity and specificity to neck dissection related QoL (Table 4). 
 
The Performance Status Scale for Head and Neck Cancer is a clinician-rated instrument. The 
three domains are understandable speech, normalcy of diet and eating in public. Three 
separate studies used the PSS-HN, one in conjunction with H&N35 and EORTC QLQ-C30 
and one in conjunction with the MD Anderson Dysphagia inventory (Table 4). The studies 
showed that chemoradiotherapy causes a deterioration in QoL but that there is no difference 
between different chemoradiotherapy regimes. 
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Functional Assessment of Cancer Therapy-Head and Neck is a self-reported instrument; the 
domains are physical, social, emotional, and functional well-being. Five studies in this review 
used FACT-HN, reporting it useful for functional assessment; the papers evaluated the 
difference in efficacy and QoL between different chemoradiotherapy regimes. There was 
found to be no difference in QoL between treatment and control groups in all the studies. 
Simon et al38 reported low completion rates (60%) in their study comparing Gefitinib with 
methotrexate. Most studies reported the FACT-HN’s utility in measuring functional 
performance for patients with head and neck cancer. (Table 4) 
 
The FHNSI-10 is aimed at patients with refractory, recurrent or advanced disease. It is a 
subset of the FACT H&N and was designed to capture physical symptoms of disease. Two 
studies used the FHNSI-10; Stewart et al43 utilised it in conjunction with the Functional 
Assessment of Cancer Therapy H&N instrument, as they reported that FHNSI-10 is 
ineffective for assessing general QoL. Again, the studies were assessing different 
chemotherapy regimens; no mention was made of patient acceptability70. 
 
The MD Anderson Dysphagia Inventory (MDADI) is a self-administered instrument for 
assessing dysphagia; it includes items grouped into domains of dysphagia; global, emotional, 
functional and physical. The inventory was used by two studies in our review both of which 
praised it for its specific use with swallowing, but also used a more general measure 
alongside (Table 4). Hutcheson et al45 used the study to assess QoL following 
chemoradiotherapy which was found to decrease. 
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The Head and Neck Radiotherapy Questionnaire is directed towards physical symptoms of 
skin, throat, stomatitis, digestion, energy and psychosocial for head and neck radiotherapy 
patients. All four of the studies that used this instrument were related to the prevention of 
xerostomia in patients undergoing radiotherapy; most radioprotective agents did not have a 
significant effect on QoL. Ringash et al complimented the disease specificity and ease of 
completion, however they also comment that data from healthy individuals is not available 
and while the score can remain the same the patients may have swapped pre-treatment 
problems with post-treatment problems73. 
 
HNQoL is a validated QoL instrument divided into four domains: eating and swallowing, 
communication, head and neck pain and emotional wellbeing. The only study to utilise this 
instrument identified QoL between patients who underwent chemoradiotherapy plus a neck 
dissection versus chemotherapy alone; no difference in QoL was found. Donatelli-Lassig et 
al59 determined that the disease specificity of the HNQoL was a useful feature. 
 
Head and Neck Cancer inventory (HNCI) is a reliable validated health status instrument. 
Lazarus et al55 utilised this study in assessing swallowing and tongue strength exercises in 
patients who underwent primary chemotherapy with or without adjuvant chemotherapy. 
Those who underwent exercises had an increase in QoL. 
 
Miscellaneous Instruments  
The Hospital Anxiety and Depression Scale is an instrument with two domains (anxiety and 
depression)75. Four studies in the sample used the HADS which focussed on whether 
implantation of coping strategies improved QoL, which was found to be the case. All the 
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studies commented that it was a useful psychological test, but Scheifke et al9 commented the 
need to use another instrument for a more rounded assessment. 
 
The Dermatology life quality index is a dermatology-specific QoL instrument76. It was 
utilised by one trial in the search which was based on skin symptoms associated with 
etuximab. The trial also used the EORTC QLQ-C30 (Table 4).  
 
The Hearing Handicap Inventory for the Elderly is a specific instrument for assessing QoL 
issues due to hearing loss. The instrument is valid, reliable and easy to use77. Schultz et al57 
were the only study to use this instrument, utilising it for hearing loss associated with head 
and neck cancer, showing that patients undergoing radiotherapy are more likely to have 
hearing related problems. 
 
The Modified WHO performance status scale is a five-point scale based on ability to work 
and is not a true QoL instrument78; it was utilised by Correy et al56 in the assessment of PEG 
vs NG tubes, where there was found to be no significant different in QoL. 
 
Conclusion 
There have been a variety of questionnaires used in clinical trials following H&N cancer; 
these have tended to be secondary outcomes. It is important when focusing on patient 
reported outcomes to include a validated questionnaire that is optimal to the hypothesis being 
tested between arms of the trial. It is worthwhile considering more than one questionnaire and 
to be as specific as possible in selection; in addition, anchoring a PROM with an objective 
measurement will be beneficial in ensuring the patient experience as the primary outcome. 
Although underlying issues have been widely discussed, three of our criteria: 
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appropriateness, precision and interpretability, are not always included in lists of desirable 
properties of instruments. The remaining five criteria are widely cited and identified in the 
same or similar terminology as in this review (Table 1). 
 
In this review, the main areas where PROs were used in clinical trials were for evaluating the 
differences between different chemotherapy medications, the differences in techniques for 
preventing xerostomia, and between different radiotherapy regimes, amongst others. For the 
main, there was little difference in QoL between different treatment regimens; those papers 
that focussed on specific patient experience measures such as implementation of coping 
strategies, found an increase in QoL. In the future, trials can be broadened to include PROs as 
the primary outcome with an explicit hypothesis. 
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Validity 
Reliability 
Responsiveness 
Appropriateness 
Precision 
Interpretability 
Acceptability 
Feasibility 
Table 1. Criteria required to be evidenced by the instruments 
 
 
 
Type of PRO 
instrument 
Number of 
instruments 
Names of instruments 
General 2 EQ-5D; COOP-WONCA 
Cancer Specific 3 EORTC QLQ C30; Spitzer QoL; Rotterdam Symptom 
Checklist 
Head & Neck 
Cancer Specific 
13 EORTC QLQ-H&N35; University of Washington QoL; 
ROTG Modified University of Washington QoL; 
University of Michigan Xerostomia Questionnaire; 
QoL-RTI; NDII; PSS H&N; MD Anderson Dysphagia 
Inventory; FACT H&N, FHNSI-10; H&N QoL; HNCI; 
H&N Radiotherapy Questionnaire 
25 
 
Miscellaneous 4 Hospital Anxiety & Depression Scale; Hearing 
Handicap Inventory; Dermatology Life Questionnaire; 
Modified WHO PS 
Table 2. Types of Patient Reported Outcome (PRO) instrument used 
Focus of the Trial Number of Trials with this Focus 
Chemotherapy/ Chemoradiotherapy regimes 13 
Xerostomia/ Mucositis 12 
Radiotherapy regimes 11 
Dietary intake 3 
Psychosocial interventions 2 
Pain medications 2 
QoL 2 
Coping strategies 2 
PET CT vs SND for monitoring 1 
Hyperbaric oxygen therapy 1 
Utilising EMG studies 1 
Shoulder exercises 1 
Dermatitis 1 
Hearing Loss 1 
Swallowing 1 
Table 3. Focus of clinical trials 
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Figure 1 Search results included in the review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified 
through database 
searching (n =2072 ) 
Sc
re
en
in
g 
In
clu
de
d 
El
ig
ib
ili
ty
 
Id
en
tif
ica
tio
n 
Records after 
duplicates removed 
 (n =1629) 
Records screened 
(n =1342) 
Records 
excluded  
(n=287) 
 
  
Full-text articles 
assessed  
for eligibility (n = 621) 
Full-text 
articles 
excluded, with 
reasons  
(n =721) 
Articles included in 
the study 
(n =54) 
27 
 
 
 
 
Questionnaire 
 
First Author/ Year Focus of the RCT Number of 
patients 
Inclusion & Exclusion 
Criteria 
Main Advantages Main Disadvantages Other Instruments 
EORTC QLQ-
C30 
Duncan et al 20056 Xerostomia/Mucositis 138 Non-metastatic; had RT Broad view of QoL 
Brief 
Validated 
Not specific to oral cavity as 
needed 
Not H&N specific 
 
 
Rivera et al 20097 Chemotherapy in 
metastatic disease 
442 Recurrent or metastatic 
cancer 
Cancer-specific 
Self-administered 
Multi-dimensional 
 
HN35 
 
Machiels et al 20158 Chemotherapy in 
metastatic disease 
483 Recurrent or metastatic 
cancer 
Cancer-specific 
Validated 
 
HN35 
 
Potthoff et al 20149 Medication for pain 
intensity 
34 Cetuximab 
chemoradiotherapy 
rhagades 
Cancer-specific 
Broad view of heath 
Pt recorded 
 
Dermatological Life  
Quality Index 
 
Bottomley et al 
201310 
Chemotherapy vs 
chemoradiotherapy 
450 Neck nodes but no 
metastases 
Broad view of health 
 
H&N35 
 
Van Herpen et al 
201011 
Symptom control 358 Unresectable, advanced 
SCC 
Robust 
Validated 
Frequently used in RCTs 
Functional & symptomatic 
scales 
Not H&N specific H&N35 
 
Machiels et al 201412 Chemotherapy in 
metastatic disease 
474 Recurrent SCC not 
amenable to salvage 
Good scale for measuring 
pain 
 
H&N35 
 
Mesia et al 201013 Chemotherapy medication 442 Previously untreated 
advanced SCC 
Cancer-specific 
Broad view of heath 
Lack of compliance to 
completion 
H&N35 
 
Schiefke et al 200814 QoL after SND 49 Sentinel node bx or SND Validated 
Reliable 
May need large numbers for 
statistical significance 
H&N35 
Hospital Anxiety and 
Depression Scale 
28 
 
 
Ackerstaff et al 
200815 
Chemotherapy medication 207 Ineligible for salvage 
surgery 
Validated 
 
H&N35 
 
Vilela et al 200516 Coping strategy therapy 101 Completed cancer 
treatment 
Validated 
 
Hospital Anxiety and  
Depression Scale 
 
Heukelom et al 
201317 
Chemoradiotherapy 268 T3/4 tumour new 
diagnosis 
Validated 
 
H&N35 
 
Uster et al 201318 Dietary intake post H&N 
cancer 
58 Those who would benefit 
from nutritional support 
Cancer-specific Not specific to nutrition  
 
Mehanna et al 201619 PET-CT in advanced SCC 564 N2 or N3 metastases Validated 
Frequently used 
Not H&N specific EQ-5D 
Hi 35 
MD Anderson dysphagia 
 
Teguh et al 200920 Hyperbaric oxygen 19 RT treatment tongue SCC Validated 
 
Performance Status Scale for 
Head and Neck Cancer 
H&N35 
 
Fang et al 200821 Different RT rxs 203 Requiring radical RT Validated 
 
H&N35 
 
Van bokhorst et al 
200022 
Enteral nutrition 49 Malnourished Cancer-specific 
Validated 
 
COOP-WONCA 
 
Myers et al 199923 Psychosocial intervention 47 H&N SCC, no previous 
mental health issue 
Cancer-specific 
 
Hospital Anxiety and  
Depression Scale 
EORTC QLQ-
H&N35 
Rivera et al 20097 Chemotherapy in 
metastatic disease 
442 Recurrent or metastatic 
cancer 
H&N cancer-specific Low completion 
May not be relevant for 
general QoL factors 
EORTC QLQ-C30 
 
Machiels et al 20158 Chemotherapy in 
metastatic disease 
483 Recurrent or metastatic 
cancer 
Validated 
 
EORTC QLQ-C30 
 
Bottomley et al 
201310 
Chemotherapy vs 
chemoradiotherapy 
450 Neck nodes but no 
metastases 
Designed for surgery, 
radiotherapy and 
chemoradiotherapy 
 
EORTC QLQ-C30 
 
Van Herpen et al 
201011 
Symptom control 358 Unresectable, advanced 
SCC 
Specific to H&N i.e. 
xerostomia etc, Good 
previous use in caner clinical 
trials 
 
EORTC QLQ-C30 
29 
 
 
Machiels et al 201412 Chemotherapy in 
metastatic disease 
474 Recurrent SCC not 
amenable to salvage 
H&N specific 
 
EORTC QLQ-C30 
 
Mesia et al 201013 Chemotherapy medication 442 Previously untreated 
advanced SCC 
H&N specific 
 
EORTC QLQ-C30 
 
Van Rij et al 200824 Xerostomia related to RT 192 For curative RT Good for xerostomia 
 
 
 
Bower et al 200925 Effects of treatment 
modalities for H&N 
231 Any form of curative Rx Validated 
H&N specific 
 
 
 
Schiefke et al 200814 QoL after SND 49 Sentinel node bx or SND Validated 
Reliable 
H&N specific 
May need large numbers for 
statistical significance 
EORTC QLQ-C30 
Hospital Anxiety and 
Depression Scale 
 
Ackerstaff et al 
200815 
Chemotherapy 
medications 
207 Ineligible for salvage 
surgery 
Validated 
 
EORTC QLQ-C30 
 
Heukelom et al 
201317 
Chemoradiotherapy 268 T3/4 tumour new 
diagnosis 
Validated 
 
EORTC QLQ-C30 
 
Mehanna et al 201619 PET-CT in advanced SCC 564 N2 or N3 metastases H&N specific 
 
MD Anderson  
Dysphagia Inventory 
 
Teguh et al 200920 Hyperbaric oxygen 19 RT treatment tongue SCC H&N specific i.e swallowing 
 
Performance Status Scale for 
Head and Neck Cancer 
EORTC QLQ-C30 
 
 
Fang et al 200821 Different RT regimes 203 Requiring radical RT Validated 
H&N specific 
 
EORTC QLQ-C30 
University of 
Michigan 
Xerostomia 
Questionnaire 
Chang et al 200926 Xerostomia 15 Disease free 1yr post-
surgery; had RT 
Simple 
Validated 
Not suitable for less invasive 
RT treatments w/ lower doses 
 
 
Scrimger et al 200727 Saliva Production 188 Bilateral RT to parotids Specific to clinical question 
 
UoWQoL 
 
Warde et al 200028 Xerostomia 28 RT; no anticholinergic 
medications 
Simple 
 
 
30 
 
 
Lin et al 200329 Xerostomia 36 Post-parotid sparing RT H&N specific 
Validated 
Specific to xerostomia 
May not be as useful when 
sample size small 
 
University of 
Washington QoL 
Scrimger et al 200727 Saliva Production 188 Bilateral RT to parotids Well-rounded general health 
view 
Insensitivity when related to 
question of xerostomia 
University of Michigan  
Xerostomia Questionnaire 
 
Parikh et al 201130 Electromyographic 
studies 
38 Selective neck dissection Good for functional 
measures 
 
Neck Dissection  
Impairment Index 
 
Lydiatt et al 200831 Depression medication 23 No pre-existing mental 
health condition 
Self-administered 
Focuses on aspects of daily 
life 
 
 
 
Brennan et al 200932 Staged vs elective neck 
treatment 
25 T1-2 N0 SCC new 
diagnosis 
General health view 
 
 
 
Oton-Leite et al 
201133 
Laser therapy with RT 60 Undergoing RT salivary 
glands 
Simple 
Brief 
Validated 
Easy to complete and 
interpret 
H&N cancer-specific 
 
 
 
Owen et al 201134 Radio frequency ablation 21 Unresectable SCC or 
previously failed Rx 
H&N specific Lack of compliance to 
completion 
 
 
Jha et al 200035 RT induced xerostomia 16 Eligible for RT General health view Not specific to xerostomia or 
RT 
 
 
Johnson et al 200236 Radioprotection of 
mucosa 
33 Resection + RT Good for functional 
measures 
heavily weighted on patient 
symptoms 
 
 
Jha et al 200337 Xerostomia 76 Requiring RT Good for functional 
measures 
 
 
RTOG-modified 
University of 
Washington QoL 
H&N Symptom 
Hoffman et al 201438 GM-CSF effect of RT 
symptoms 
114 No previous 
chemoradiotherapy 
Self-administered 
Validated 
Specific to RT 
Lack of compliance to 
completion 
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Heron et al 200939 Stereotactic body 
radiotherapy 
25 Recurrent SCC General health but with 
specific RT aspect 
 
 
 
Fisher et al 200340 Xerostomia post RT 249 RT Function specific 
Good for RT 
 
 
Neck Dissection 
Impairment 
Index 
Parikh et al 201130 Electromyographic 
studies 
38 Selective neck dissection Simple 
 
University of Washington  
QoL 
 
McNeely et al 200841 Exercise for shoulder pain 52 Neck dissection, shoulder 
dysfunction 
Specific for neck dissection 
issues 
 
Functional Assessment  
of Cancer Therapy 
H&N 
FHNSI-10 Kushwaha et al 
201542 
Palliative chemotherapy 
medications 
117 Pt ineligible for salvage 
surgery/RT/chemo 
Specific for 
advanced/recurrent cancer 
Brevity 
 
 
 
Stewart et al 200943 Methotrexate recurrent 
SCC 
486 Recurrent SCC with RT 
not amenable to salvage 
Good for symptomatic 
measures 
Not useful for general health Functional Assessment of 
Cancer Therapy H&N 
Performance 
Status Scale for 
Head and Neck 
Cancer 
Mittal et al 201544 Swallowing/ Saliva 
Production 
13 Chemoradiotherapy H&N cancer-specific 
 
 
 
Hutcheson et al 
201445 
Chemotherapy in relation 
to swallowing 
47 Untreated stage IV SCC Disease specific, Involves 
another person i.e. the 
clinician 
Involves another person i.e. 
the clinician 
MD Anderson 
Dysphagia Inventory 
 
Teguh et al 200920 Hyperbaric oxygen 19 RT treatment tongue SCC Good for functional 
activities such as swallowing 
 
H&N35 
EORTC QLQ-C30 
Functional 
Assessment of 
Cancer Therapy 
H&N 
Rischin et al 201046 Chemoradiotherapy 
effectiveness 
850 Previously untreated 
advanced SCC 
H&N cancer-specific 
Good for 
chemo/radiotherapy Rx 
options 
 
 
 
Simon et al 200943 Methotrexate recurrent 
SCC 
486 Recurrent SCC with RT 
not amenable to salvage 
H&N cancer-specific Low completion FHNSI-10 
32 
 
 
Cohen et al 200647 Chemoradiotherapy 53 Stage II or III SCC Good focus on chemo and 
radiotherapy options 
 
 
 
McNeely et al 200841 Exercise for shoulder pain 52 Neck dissection, shoulder 
dysfunction 
Good for function & 
exercise 
 
Neck Dissection  
Impairment Index 
 
Ringash et al 200848 RT 171 Locally advanced SCC 
III/IV 
Good for function 
Good for RT 
 
 
MD Anderson 
Dysphagia 
Inventory 
Hutcheson et al 
201445 
Chemotherapy in relation 
to swallowing 
47 Untreated stage IV SCC Specific to swallowing Needs to be used in 
conjunction with another 
questionnaire for more 
rounded assessment 
Performance Status Scale for 
Head and Neck Cancer 
 
Mehanna et al 201619 PET-CT in advanced SCC 564 N2 or N3 metastases Another more specific 
dimension related to H&N 
 
H&N35 
Spitzer QoL 
Index 
Robert et al 199749 Chemotherapy 
medications 
26 Recurrent or metastatic 
cancer 
Related to basic living tasks Not H&N cancer specific  
 
Elliot et al 200650 Prevention of radiation 
dermatitis 
547 Stage III or IV SCC 
requiring RT 
Validated 
Self-assessment 
May be subject to reviewer or 
pt bias 
Head and Neck 
Radiotherapy Questionnaire 
Hospital Anxiety 
and Depression 
Scale 
Griffiths et al 199951 Physical & Psychological 
symptoms 
615 SCC treatment Psychologically specific Data needs to be analysed in 
several ways to ensure 
consistency 
Rotterdam Symptom  
Checklist 
 
Schiefke et al 200814 QoL after SND 49 Sentinel node bx or SND Psychologically specific Needs to be used in 
conjunction with another 
questionnaire for more 
rounded assessment 
 
EORTC QLQ-C30 
 
Vilela et al 200516 Coping strategy therapy 101 Completed cancer 
treatment 
Psychologically specific 
 
EORTC QLQ-C30 
 
Myers et al 199923 Psychosocial intervention 47 H&N SCC, no previous 
mental health issue 
Psychologically specific 
 
EORTC QLQ-C30 
Head and Neck 
Radiotherapy 
Questionnaire 
Elliot et al 200650 Prevention of radiation 
dermatitis 
547 Stage III or IV SCC 
requiring RT 
H&N cancer-specific 
RT specific 
May be subject to reviewer or 
pt bias 
Spitzer QoL Index 
33 
 
 
Ringash et al 200552 Post-RT xerostomia 130 RT to parotids Validated 
Cancer-specific 
RT specific 
Multi-dimensional 
Easy to complete 
Questionnaire disease specific 
Uses summary scores so may 
not be adequate for 
xerostomia assessment 
Does not assess patient 
weighting of problem 
 
 
Wong et al 200353 TENS post RT 37 Xerostomia post radial RT Easy to complete 
 
 
 
Warde et al 200254 Oral pilocarpine for RT 130 RT with inclusion of 
parotids 
RT specific 
 
 
EQ-5D Mehanna et al 201619 PET-CT in advanced SCC 564 N2 or N3 metastases Good for cost effectiveness 
assessment 
 
EORTC QLQ-C30 
H&N35 
MD Anderson dysphagia 
Head and Neck 
Cancer Inventory 
Lazarus et al 201355 Swallowing/ Tongue 
strength 
23 Post-op SCC resection; no 
pre-existing dysphagia 
Good for functional scores 
 
 
Modified WHO 
Performance 
Status Scale 
Corry et al 200856 PEG vs NG 33 RT and needing enteral 
feeding 
Specific to NG tubes 
Simple 
Not related to cancer  
Dermatological 
Life Quality 
Index 
Potthoff et al 20149 Medication for pain 
intensity 
34 Cetuximab 
chemoradiotherapy 
rhagades 
Specific to dermatology Not related to H&N cancer EORTC QLQ-C30 
Rotterdam 
Symptom 
Checklist 
Griffiths et al 199951 Physical & Psychological 
symptoms 
615 SCC treatment Cancer specific 
General view of heath 
Pt recorded 
 
Hospital Anxiety and 
Depression Scale 
Hearing 
Handicap 
Inventory for the 
Elderly 
Schultz et al 201057 Hearing loss of H&N 
cancer patients 
141 Had RT Specific to hearing loss Not relevant for any other 
features of H&N cancer 
 
QoL-RTI Maguire et al 201158 RT therapy in advanced 
SCC 
30 Stage III or IV SCC 
requiring RT 
Radiation and RT specific 
Good for swallowing 
measurements 
Not related to other aspects of 
H&N cancer 
 
34 
 
COOP-WONCA Van bokhorst et al 
200012 
Enteral nutrition 49 Malnourished Generic 
Practical 
Easy 
Not specific to cancer or 
H&N 
EORTC QLQ-C30 
HNQoL Donatelli-Lassig et al 
200859 
QoL post 
chemoradiotherapy 
65 Inclusive of SND Cancer-specific 
H&N specific 
 
 
Table 4. Patient Reported Outcome Measures used in papers relevant to Head & Neck Cancer. 
